Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10342 in advanced solid tumors
NCT04060511Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-10342 in solid tumor, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Dose-Limiting Toxicity at 5 weeks and Maximum Tolerated Dose at 5 weeks. Started Jun 2019; status: completed.
02
Drugs
HS-10342
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04060511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060511.